Combining over 1,000 human antibodies, GIGA-2339 aims to achieve viral clearance and activate the immune system, offering a potential solution where current therapies fall short of providing a cure.
Carter Keller
Advertisement
Senior Vice President at Grifols and head of GigaGen.
Articles by Carter Keller
Carter Keller discusses the company's recent $135.2 million contract with BARDA to develop recombinant polyclonal antibody therapies targeting botulinum neurotoxins and an unspecified biothreat, highlighting their innovative approach to address emerging health threats.
Following FDA approval, GigaGen's therapy enters Phase 1 clinical trials as the first recombinant human polyclonal therapy for hepatitis B.
Advertisement
Latest Updated Articles
HBV Antibody GIGA-2339 Cleared for Clinical Trials to Address Hepatitis B Cure GapPublished: August 12th 2024 | Updated: August 12th 2024
GigaGen Doses First Patient in Phase 1 Trial of GIGA-2339, a Potential Functional Cure for Chronic Hepatitis BPublished: November 25th 2024 | Updated:
- GigaGen's New Contract with BARDA for Polyclonal Antibody Development
Published: October 4th 2024 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Clinical Takeaways From ViiV’s PASO DOBLE and CLARITY Studies
2
Phage and Antibiotic Combination Therapy for Biofilm-Associated Bacterial Infections
3
Streamlining IV-to-Oral Transitions in Pneumonia Care: Duration, Tailoring, and Post-Discharge Considerations
4
WHO Calls for Global Action on Growing AMR
5
